Skip to main content

Table 1 Analysis of the main characteristics of patients with rectal adenocarcinoma

From: Deep-learning model for predicting the survival of rectal adenocarcinoma patients based on a surveillance, epidemiology, and end results analysis

Variables

Overall

N(%)

Train cohort

N(%)

Test cohort

N(%)

P

Patients

49,275

34,492(70.0%)

14,783(30.0%)

 

Sex

  Female

19,771(40.1%)

13,878(40.2%)

5893(39.9%)

0.440

  Male

29,504(59.9%)

20,614(59.8%)

8890(60.1)

Age at diagnosis

  mean ± sd

62.6 ± 13.5

62.5 ± 13.5

62.7 ± 13.4

0.131

Race

  Black

4174(8.5%)

2951(8.6%)

1223(8.3%)

0.326

  White

40,063(81.3%)

28,053(81.3%)

12,010(81.2%)

  Amercian Indian/Alaska Native

390(0.8%)

279(0.8%)

111(0.8%)

  Asian or Pacific Islander

4648(9.4%)

3209(9.3%)

1439(9.7%)

Marital status at diagnosis

  Married

29,160(59.2%)

20,482(59.4%)

8678(58.7%)

0.160

  Unmarried

20,115(40.8%)

14,010(40.6%)

6105(41.3%)

Histologic#

  PA

36,549(74.2%)

25,564(74.1%)

10,985(74.3%)

0.847

  TA

10,364(21.0%)

7285(21.1%)

3079(20.8%)

  MA

1955(4.0%)

3143(3.9%)

598(4.0%)

  SRCC

407(0.8%)

423(0.9%)

121(0.9%)

Grade

  Grade I

4537(9.2%)

3143(9.1%)

1394(9.4%)

0.717

  Grade II

37,522(76.2%)

26,298(76.3%)

11,224(76.0%)

  Grade III

6616(13.4%)

4628(13.4%)

1988(13.4%)

  Grade IV

600(1.2%)

423(1.2%)

177(1.2%)

AJCC

  I

15,009(30.5%)

10,501(30.5%)

4508(30.5%)

0.888

  II

10,899(22.1%)

7601(22.0%)

3298(22.3%)

  III

15,048(30.5%)

10,546(30.6%)

4502(30.5%)

  IV

8319(16.9%)

5844(16.9%)

2475(16.7%)

T

  T0

7(0.01%)

5(0.01%)

2(0.01%)

0.616

  T1

10,071(20.4%)

7071(20.5%)

3000(20.3%)

  T2

7940(16.1%)

5502(16.0%)

2438(16.5%)

  T3

23,928(48.6%)

16,786(48.7%)

7142(48.3%)

  T4

4089(8.3%)

2832(8.2%)

1257(8.5%)

  TX

2111(4.3%)

1494(4.3%)

617(4.2%)

  Tis

1123(2.3%)

796(2.3%)

327(2.2%)

N

 N0

28,582(58.0%)

19,965(57.9%)

8617(58.3%)

0.765

 N1

13,613(27.6%)

9577(27.8%)

4036(27.3%)

 N2

5936(12.1%)

4148(12.0%)

1788(12.1%)

  NX

1144(2.3%)

802(2.3%)

342(2.3%)

M

0

   

 M0

40,934(83.1%)

28,633(83.0%)

12,301(83.2%)

0.848

 M1

8319(16.9%)

5844(16.9%)

2475(16.7%)

 MX

22(0.05%)

15(0.1%)

7(0.1%)

Summary stage

0

   

 Regional

20,563(41.7%)

14,358(41.6%)

6205(42.0%)

0.755

 Distant

19,956(40.5%)

13,986(40.5%)

5970(40.4%)

 Localized

8756(17.8%)

6148(17.9%)

2608(17.6%)

Surgery performed

0

   

 No

8367(17.0%)

5877(17.0%)

2490(16.8%)

0.597

 Yes

40,908(83.0%)

28,615(83.0%)

12,293(83.2%)

Radiotherapy

0

   

 No/Unknown

21,408(43.4%)

15,019(43.5%)

6389(43.2%)

0.505

 Yes

27,867(56.6%)

19,473(56.5%)

8394(56.8%)

Chemotherapy

0

   

 No/Unknown

18,286(37.1%)

12,836(37.2%)

5450(36.9%)

0.464

 Yes

30,989(63.1%)

21,656(62.8%)

9333(63.1%)

Status

0

   

 Death

14,078(28.5%)

9871(28.5%)

4207(28.5%)

0.790

 Alive

35,247(71.5%)

24,671(71.5%)

10,576(71.5%)

  1. #PA Papillary adenocarcinoma, morphology code 8140; TA Tubular adenocarcinoma, morphology code 8210–8221, 8261–8263; MA Mucinous adenocarcinomas, morphology code 8480; SRCC Signet ring cell carcinoma, morphology code 8490